Table 1 Baseline Patient Characteristics at Randomization (Patients Entering the Active Comparator Controlled Period – Weeks 6–52)
| Â | Etoricoxib | Diclofenac | ||
|---|---|---|---|---|
| Â | 30 mg | 60 mg | 90 mg | 150 mg |
| Â | (N = 198) | (N = 102) | (N = 148) | (N = 102) |
| Â | n (%) | n (%) | n (%) | n(%) |
Gender | Â | Â | Â | Â |
   Female | 141 (71.2) | 75 (73.5) | 100 (67.6) | 79 (77.5) |
   Male | 57 (28.8) | 27 (26.5) | 48 (32.4) | 23 (22.5) |
Mean age in years (SD) | 61.9 (10.4) | 62.3 (10.2) | 60.6 (9.6) | 62.3 (10.4) |
Race | Â | Â | Â | Â |
   White | 176 (88.9) | 89 (87.3) | 131 (88.5) | 93 (91.2) |
   Black | 15 (7.6) | 6 (5.9) | 10 (6.8) | 6 (5.9) |
   Hispanic | 7 (3.5) | 5 (4.9) | 7 (4.7) | 2 (2.0) |
   Native American | 0 (0.0) | 2 (2.0) | 0 (0.0) | 1 (1.0) |
Mean Duration of OA in years (SD) | 7.8 (7.9) | 7.5 (6.6) | 7.8 (7.4) | 7.5 (7.1) |
ARA Function Class | Â | Â | Â | Â |
   Class I | 25 (12.6) | 12 (11.8) | 25 (18.6) | 19 (18.6) |
   Class II | 134 (67.7) | 72 (70.6) | 95 (65.7) | 67 (65.7) |
   Class III | 39 (19.7) | 18 (17.6) | 27 (18.4) | 16 (15.7) |
WOMAC Pain Subscale (100 mm VAS†[Mean (SD)] | 68.4 (17.0) | 68.2 (17.7) | 67.7 (16.9) | 69.8 (16.1) |
Investigator Global Assessment of Disease Status (0 to 4 Likert Scale) [Mean (SD)] | 2.9 (0.6) | 2.8 (0.7) | 2.9 (0.6) | 2.8 (0.7) |